OakChart

Dianthus Therapeutics Inc

DNTHHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:56 AM ET

89.68+0.87 (0.98%)
2026-11-11 16:57 CET
Market cap
5,001.13 USD m
Revenue, TTM
2.72 USD m
Net income, TTM
-202.12 USD m
Free cash flow, TTM
-175.85 USD m
EPS diluted, TTM
-3.99
P/E
-
Compare

Price

DNTH against its 20, 50 and 200-day averages
2050200beatmiss
60.0080.00100.00120.002.8M5.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DNTHclose 89.6820-day 81.3950-day 89.05200-day 86.5289.6852w high

23.9% under the 52-week high of 117.88 on 19 Aug 2026. 52-week low 34.29 on 14 Nov 2025. Last 15 sessions, 21.8% high to low

Profile

DNTH
52-week range, 66% of the way up
34.29117.88

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

IndexRUT
Employees92
IPOJun 21, 2018
Beta1.45
ATR, 14d4.19
Rel volume0.99
Short float19.81%
Insider own16.86%
Inst own118.09%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.05B
Enterprise Value4.21B
Income-202.12M
Sales2.72M
Book/sh22.05
Cash/sh14.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOJun 21, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S1856.66
P/B4.07
P/C6.03
P/FCF-
EV/EBITDA-
EV/Sales1549.10
Quick Ratio30.02
Current Ratio30.02
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.99
EPS next Y-4.33
EPS next Q-0.96
EPS this Y15.75%
EPS next Y-22.29%
EPS next 5Y-7.36%
EPS past 3/5Y49.46% 31.21%
Sales past 3/5Y-31.80% -
EPS Y/Y TTM-14.33%
Sales Y/Y TTM-11.70%
EPS Q/Q16.39%
Sales Q/Q205.56%
EarningsNov 04 AMC
EPS/Sales Surpr.14.24% 162.53%

Ownership

Insider Own16.86%
Insider Trans-3.37%
Inst Own118.09%
Inst Trans-2.47%
ROA-21.81%
ROE-22.61%
ROIC-16.27%
Gross Margin85.69%
Oper. Margin-8683.89%
Profit Margin-7436.50%
SMA2010.18%
SMA500.70%
SMA2003.65%
Trades-

Technical

Shs Outstand56.30M
Shs Float46.82M
Short Float19.81%
Short Ratio11.11
Short Interest9.28M
52W High117.88 -23.92%
52W Low34.29 161.53%
Volatility6.15% 5.49%
ATR (14)4.19
RSI (14)60.34
Beta1.45
Rel Volume0.99
Avg Volume835.30K
Volume214,977

Performance

Perf Week4.51%
Perf Month15.60%
Perf Quarter-18.18%
Perf Half Y4.60%
Perf YTD117.62%
Perf Year148.42%
Perf 3Y679.83%
Perf 5Y-24.56%
Perf 10Y-
Recom1.05
Target Price138.71
Prev Close88.81
Price89.68
Change %0.98%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 27, 2026InitiatedRRoth CapitalBuy$113+26.0%
Sep 11, 2026InitiatedJJP MorganOverweight$135+50.5%
Sep 04, 2026InitiatedCCitigroupBuy$156+74.0%
Apr 09, 2026InitiatedWWolfe ResearchOutperform$98+9.3%
Mar 10, 2026UpgradeRRaymond JamesOutperform → Strong Buy$123+37.2%
Oct 14, 2025InitiatedTTruistBuy$56-37.6%
Jul 02, 2025InitiatedWWilliam BlairOutperform
Dec 20, 2024InitiatedTTD CowenBuy
Oct 03, 2024InitiatedOOppenheimerOutperform$48-46.5%
Jul 26, 2024InitiatedRRobert W. BairdOutperform$58-35.3%

Peers

Mkt cap
TickerCompanyMkt cap
IMVTImmunovant Inc7.60B
ARGXArgen X SE ADR60.85B
ANNXAnnexon Inc799.48M
VRDNViridian Therapeutics Inc3.50B
KYTXKyverna Therapeutics Inc321.58M
RNACCartesian Therapeutics Inc211.70M
SNYSanofi ADR113.71B
CABACabaletta Bio Inc302.00M
AZNAstrazeneca plc285.12B
JNJJohnson & Johnson666.70B

Insider trading

latest 14 of 67
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RYAN SAVITZOfficerNov 09 '26Proposed Sale86.03124,04210,671,333Nov 09 04:36 PM
CARR EDWARDCHIEF ACCOUNTING OFFICERSep 17 '26Option Exercise17.8820,000357,60020,000Sep 18 04:36 PM
CARR EDWARDCHIEF ACCOUNTING OFFICERSep 17 '26Sale101.3820,0002,027,6460Sep 18 04:36 PM
EDWARD CARROfficerSep 17 '26Proposed Sale102.4920,0002,049,800Sep 17 04:28 PM
Randhawa SimratEVP, Head of R&DSep 01 '26Option Exercise20.6323,124477,04727,124Sep 03 04:30 PM
Randhawa SimratEVP, Head of R&DSep 01 '26Sale106.4123,1242,460,6904,000Sep 03 04:30 PM
SIMRAT RANDHAWAOfficerSep 01 '26Proposed Sale105.6123,1242,442,126Sep 01 04:49 PM
Read SimonDirectorAug 19 '26Option Exercise18.362,77851,0042,778Aug 19 06:02 PM
Read SimonDirectorAug 19 '26Sale117.552,778326,5540Aug 19 06:02 PM
Veness Adam MSVP, General Counsel and Sec.Aug 13 '26Option Exercise18.1715,000272,55015,000Aug 14 04:30 PM
McGeorge AnneDirectorAug 10 '26Option Exercise12.527,75097,0007,750Aug 11 05:15 PM
McGeorge AnneDirectorAug 10 '26Sale109.017,750844,8220Aug 11 05:15 PM
Read SimonDirectorAug 10 '26Option Exercise18.362,77750,9862,777Aug 11 05:10 PM
Read SimonDirectorAug 10 '26Sale109.552,777304,2320Aug 11 05:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B

News

latest 14 of 206
  • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results (GlobeNewswire)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics to Participate in Five Investor Conferences During November (GlobeNewswire)
  • Dianthus Therapeutics Named to Fortune's 2026 Best Workplaces in BioPharma List Amid Company Expansion (InvestorsHub)
  • Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma (GlobeNewswire)
  • Loading…
  • Top Bank Names 6 Stocks With Major Catalysts Ahead (GuruFocus.com)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting (GlobeNewswire)
  • UiPath downgraded, Shell upgraded: Wall Street's top analyst calls (The Fly)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics to Participate in Three Investor Conferences During September (GlobeNewswire)
  • Dick's Sporting Goods shares rise after Wells Fargo upgrade (InvestorsHub)
  • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.810-0.945-0.8101.210.4616
2026Q22026-08-04-0.900-0.846-0.8960.760.3012
2026Q12026-05-05-0.850-1.072-0.8500.460.4014
2025Q42026-03-09-1.430-1.006-1.4330.280.5512
2025Q32025-11-05-0.970-0.868-0.9730.400.5814
2025Q22025-08-07-0.880-0.872-0.8830.190.8612
2025Q12025-05-12-0.820-0.850-0.8251.160.8110
2024Q42025-03-11-0.810-0.851-0.8121.330.9611
2024Q32024-11-07-0.740-0.595-0.7352.170.749
2024Q22024-08-08-0.510-0.545-0.5141.860.379
2024Q12024-05-09-0.540-0.438-0.5360.870.465
2023Q42024-03-21-0.710-0.940-0.7130.460.555
2023Q32023-11-09-3.780-0.560-3.7790.920.252
2023Q22023-09-18-2.945-0.800-0.8660.980.001
2023Q12023-05-15-7.520-6.560-7.6960.000.001
2022Q42023-03-23-4.800-4.320-5.3240.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-33.120-32.293-33.1840.000.00
2020FY-27.360-26.944-27.2990.000.00
2021FY-20.640-19.535-20.7130.000.00
2022FY-18.240-18.788-32.5730.000.00
2023FY-8.450-5.530-8.4522.832.46
2024FY-2.550-2.561-2.5516.245.54
2025FY-4.200-3.676-4.1882.042.20
2026FY--3.539--2.52
2027FY--4.328--2.30
2028FY--5.197--13.96
2029FY--3.816--207.36
2030FY-1.833--744.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0515200.440.001.21
2026Q4S2026-11-0415000.380.001.00
2026Q4S2026-10-2615000.380.001.00
2026Q4S2026-10-1914000.360.001.00
2026Q4S2026-09-2914200.360.001.00
2026Q4S2026-09-1014300.360.001.00
2026Q4S2026-09-0413300.390.001.00
2026Q4S2026-08-0512300.390.001.00
2026Q4S2026-07-2011000.300.001.00
2026Q4S2026-06-1711210.300.001.00
2026Q4S2026-05-0712210.300.001.00
2026Q4S2026-05-0613210.370.001.20
2026Q4S2026-04-0713010.390.001.20
2026Q4S2026-03-1812010.400.001.20

Estimate history

EPS, annual-17.274-50.118-33.184-27.299-20.713-32.573-8.452-2.551-4.204-3.9925
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.735-0.812-0.825-0.883-0.973-1.433-0.85-0.896-0.813
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000006.4172.8266.2352.0362.72
Period201720182019202020212022202320242025TTM
Sales, quarterly2.1721.3261.1630.1930.3960.2840.4630.7611.21
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.0562.0822.4543.0333.6750.87514.81831.11543.22356.295
Period201720182019202020212022202320242025MRQ
Shares, quarterly29.36631.11532.12632.17642.85543.22354.58354.79856.295
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.722.046.242.836.420.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.430.410.350.152.021.981.840.88
Gross Profit2.331.615.822.476.27-2.02-1.98-1.84-0.88
Selling, General and Administrative Excl. Other238.36179.54107.6950.6535.9872.6776.7281.1359.09
Research and Development188.71145.6483.1132.8429.3844.7548.6457.3741.34
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-236.03-177.93-101.86-48.17-29.70-74.69-78.70-82.97-59.96
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Net Income From Continuing Operations-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.60
EPS (Recurring)-3.52-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EPS (Basic, Before Extraordinaries)-3.99-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EPS (Diluted)-3.99-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EBITDA-235.64-177.50-101.45-47.82-29.56-72.67-76.72-81.13-59.09
Non-Operating Income (Expense)33.9015.6016.894.621.233.563.776.202.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense41.2022.7912.892.901.5210.319.9410.0010.70
Price To Sales Ratio1,857.58781.65116.4818.970.86----
Gross Margin85.6978.9893.3987.4497.71----
Operating Margin-8,683.89-8,739.34-1,633.74-1,704.67-462.91----
Net Margin-7,436.50-7,973.33-1,362.77-1,541.22-443.76----
Shares Outstanding56.3043.2231.1214.820.883.673.032.452.08
Market Capitalization5,001.135,001.13645.21154.1023.92260.48380.50595.19189.84

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.210.760.460.280.400.191.161.33
Cost of Goods Sold Incl. D&A0.110.110.080.100.100.100.130.08
Gross Profit1.100.650.390.190.300.091.031.25
Selling, General and Administrative Excl. Other59.5762.1446.9269.7340.5935.0234.2133.16
Research and Development45.6048.6934.5359.9032.4926.2527.0026.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-58.47-61.48-46.53-69.54-40.29-34.93-33.18-31.92
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Net Income From Continuing Operations-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Net Income-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
EPS (Recurring)-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EPS (Basic, Before Extraordinaries)-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EPS (Diluted)-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EBITDA-58.36-61.38-46.46-69.44-40.19-34.83-33.04-31.84
Non-Operating Income (Expense)11.8311.275.705.113.523.303.673.48
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.7211.9010.605.985.795.715.323.92
Price To Sales Ratio1,857.582,868.553,017.15910.25483.17137.4999.52122.49
Gross Margin90.9985.9483.5965.8575.0048.7088.5694.12
Operating Margin-4,832.40-8,079.11-10,050.32-24,486.27-10,173.74-18,096.89-2,852.71-2,406.94
Net Margin-3,854.79-6,598.55-8,819.44-22,687.32-9,284.09-16,388.08-2,537.49-2,144.80
Shares Outstanding56.3054.8054.5843.2242.8532.1832.1331.12
Market Capitalization5,001.135,328.864,442.901,766.921,566.77599.14582.75645.21

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments404.30275.24173.7275.49176.93148.84145.73142.5751.57
Short Term Receivables0.101.010.485.640.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.044.663.250.913.772.694.112.750.94
Total Current Assets409.44280.90177.4582.03180.69151.53149.84145.3252.50
Net Property, Plant & Equipment1.631.750.800.967.468.319.893.071.74
Total Investments and Advances110.1481.730.070.061.781.781.788.920.22
Intangible Assets---0.000.000.000.000.00-
Deferred Tax Assets0.480.23-------
Other Assets9.729.631.090.060.000.000.000.000.00
Total Assets531.40374.24179.4183.11189.93161.62161.51157.3154.46
Short Term Debt Incl. Current Port. of LT Debt0.370.320.420.350.000.000.000.000.00
Accounts Payable9.724.582.611.173.043.762.813.490.17
Other Current Liabilities20.6413.556.606.717.827.6711.306.933.98
Total Current Liabilities30.7318.459.638.2210.8611.4314.1210.424.14
Long Term Debt1.021.170.170.440.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.480.23-------
Other Liabilities5.771.910.740.796.406.286.211.250.00
Total Liabilities38.0021.7610.549.4517.2617.7120.3211.664.14
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00118.020.000.000.000.0092.44
Common Equity493.40352.48168.87-44.37172.67143.91141.19145.65-42.12
Total Shareholders Equity493.40352.48168.8773.66172.67143.91141.19145.6550.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity493.40352.48168.8773.66172.67143.91141.19145.6550.32
Total Liabilities & Stockholders Equity531.40374.24179.4183.11189.93161.62161.51157.3154.46
Book Value Per Share11.4211.3311.40-50.6946.9947.4457.5469.97-20.49
Tangible Book Value Per Share11.4211.3311.40-50.6946.9947.4457.5469.97-20.49
Full-Time Employees92785347756972--
Price to Book Ratio4.031.890.860.191.512.644.221.301.18
Return on Assets-35.85-30.69-26.72-20.86-40.47-46.38-48.16-54.32-107.87
Return on Equity-38.38-32.60-31.70-23.12-44.94-52.57-53.53-58.70-119.57
Return on Invested Capital-32.83-24.03-25.77-38.43-41.20-52.07-54.37-39.49-70.53
Quick Ratio13.3215.2218.429.9716.6313.2610.6213.9512.68
Current Ratio13.3215.2218.429.9716.6313.2610.6213.9512.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Depreciation0.390.430.410.350.152.021.981.840.88
Other Funds (Non Cash)32.5116.126.731.480.9111.1110.128.9910.77
Funds from Operations-169.23-145.79-77.83-41.72-27.42-58.01-62.84-65.93-45.87
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.9316.73-0.354.86-1.65-1.53-1.198.833.98
Cash from Operating Activities-175.15-129.06-78.18-36.86-29.07-59.53-64.02-57.10-41.89
Capital Expenditures-0.70-0.21-0.10-0.11-0.14-1.26-0.40-3.06-7.67
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.01
Purchase or Sale of Investments-686.46-122.62-286.7120.36-59.6844.69-10.234.59-84.04
Purchase of Investments-1,182.19-435.01-413.71-57.42-61.68-45.31-95.73-144.37-84.04
Sale Or Maturity of Investments495.73312.39127.0077.782.0090.0085.50148.960.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-687.16-122.83-286.8120.25-59.8243.43-10.631.53-91.70
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock862.15280.12255.620.0196.6889.6067.7462.30142.15
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock862.15280.12255.620.0196.6889.6067.7462.30142.15
Proceedsfrom Stock Options833.05272.22254.530.0096.6886.2464.6760.28142.12
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00133.570.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-8.170.000.000.000.000.00
Cash from Financing Activities862.15280.12255.62133.5796.6889.6067.7462.30142.15
Net Change in Cash-0.1728.23-109.37116.977.7973.50-6.926.738.56
Free Cash Flow-175.85-129.27-78.28-36.97-29.21-60.80-64.42-60.16-49.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments837.78886.811,111.26404.30402.61257.39
Short Term Receivables0.630.311.310.105.000.14
Inventories0.000.000.000.000.000.00
Other Current Assets17.6210.427.345.046.216.08
Total Current Assets856.04897.541,119.91409.44413.82263.61
Net Property, Plant & Equipment1.901.641.571.631.491.58
Total Investments and Advances406.04303.80114.04110.14153.0451.94
Deferred Tax Assets---0.48--
Other Assets12.2710.2911.379.729.098.95
Total Assets1,276.251,213.271,246.88531.40577.45326.08
Short Term Debt Incl. Current Port. of LT Debt0.350.370.400.370.220.21
Accounts Payable5.506.395.279.726.715.40
Other Current Liabilities22.6727.6232.6120.6416.9314.48
Total Current Liabilities28.5234.3938.2830.7323.8620.09
Long Term Debt0.860.910.961.021.071.12
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.48--
Other Liabilities5.455.946.325.776.071.78
Total Liabilities34.8241.2545.5738.0030.9923.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,241.431,172.031,201.31493.40546.45303.08
Total Shareholders Equity1,241.431,172.031,201.31493.40546.45303.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,241.431,172.031,201.31493.40546.45303.08
Total Liabilities & Stockholders Equity1,276.251,213.271,246.88531.40577.45326.08
Book Value Per Share22.0521.3922.0111.4212.759.42
Tangible Book Value Per Share22.0521.3922.0111.4212.759.42
Full-Time Employees---92--
Price to Book Ratio4.034.437.353.234.181.82
Return on Assets-21.81-24.98-21.77-35.85-27.12-33.02
Return on Equity-22.61-26.07-22.70-38.38-28.57-34.71
Return on Invested Capital-3.75-4.28-3.40-13.03-6.71-10.40
Quick Ratio30.0226.1029.2513.3217.3513.12
Current Ratio30.0226.1029.2513.3217.3513.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-46.64-50.22-40.83-64.43-36.77-31.63
Depreciation0.110.110.080.100.100.10
Other Funds (Non Cash)11.816.149.694.873.264.59
Funds from Operations-34.72-43.97-31.07-59.47-33.41-26.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-15.61-5.012.2212.482.853.05
Cash from Operating Activities-50.33-48.98-28.86-46.98-30.55-23.89
Capital Expenditures-0.37-0.18-0.01-0.14-0.01-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-111.51-478.34-133.9637.34-201.2726.49
Purchase of Investments-323.10-565.76-238.59-54.73-279.84-33.11
Sale Or Maturity of Investments211.6087.43104.6292.0878.5759.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-111.87-478.52-133.9737.20-201.2826.45
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock107.4710.38739.414.88274.510.57
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock107.4710.38739.414.88274.510.57
Proceedsfrom Stock Options98.31-0.20735.13-0.19272.28-0.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities107.4710.38739.414.88274.510.57
Net Change in Cash-54.73-517.12576.58-4.9042.683.12
Free Cash Flow-50.70-49.16-28.87-47.12-30.56-23.94

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 6.24M 2025: 2.04M
United States2024: 6.24M 2025: 2.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.81%9.3M46.8M817.10K
2026-10-1519.32%9.0M46.5M809.00K
2026-09-3019.65%9.1M46.5M832.97K
2026-09-1518.98%8.8M46.5M932.88K
2026-08-3116.69%8.4M50.5M1.04M
2026-08-1418.10%8.4M46.5M1.05M
2026-07-3117.85%8.4M46.9M1.01M
2026-07-1520.10%9.2M45.9M933.25K
2026-06-3020.78%9.5M45.9M910.98K
2026-06-1515.22%7.0M45.9M822.95K
2026-05-2913.52%6.7M49.5M931.50K
2026-05-1513.00%6.4M49.5M932.56K
2026-04-3012.93%6.6M50.7M967.74K
2026-04-1514.50%6.6M45.3M1.07M
2026-03-3120.56%9.1M44.1M1.08M
2026-03-1324.81%9.2M37.1M978.27K
2026-02-2721.91%7.9M36.0M731.36K
2026-02-1322.49%8.1M36.0M797.54K
2026-01-3024.01%8.3M34.6M778.61K
2026-01-1523.80%7.4M31.0M689.84K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.0047.1051.500.004.3820.000.000.931-0.4620.019
call45.0042.1046.500.003.8390.000.000.921-0.4520.021
call50.0037.0041.5043.633.3562.000.000.909-0.4400.023
call55.0032.4036.500.002.9760.000.000.895-0.4240.025
call60.0027.1031.5017.802.67413.000.000.878-0.4050.028
call65.0022.5026.5035.892.2901.000.000.858-0.3830.031
call70.0017.6021.508.751.9144.000.000.833-0.3570.035
call75.0012.8016.507.551.5021020.000.800-0.3270.039
call80.008.3012.006.251.2965,3800.000.747-0.2830.045
call85.004.508.503.751.17520.000.000.650-0.2600.052
call90.001.504.902.480.9741260.000.494-0.2910.056
call95.000.004.900.691.2821050.000.409-0.3680.055
call1000.003.401.151.2604.000.000.312-0.3470.050
call1050.150.850.800.9276.000.000.138-0.1580.031
call1100.004.900.931.06411.000.000.123-0.1690.029
call1150.004.900.451.21812.000.000.111-0.1790.027
call1200.004.900.251.36734.000.000.102-0.1890.025
call1250.004.900.301.5001.000.000.095-0.1960.024
call1300.004.908.201.6271.000.000.089-0.2030.023
call1350.004.902.351.7447.000.000.084-0.2090.022
call1400.004.900.101.85196.000.000.081-0.2140.021
call1450.004.900.301.9561.000.000.077-0.2190.020
call1500.004.900.002.0640.000.000.074-0.2250.020
call1550.001.152.252.1552.000.000.072-0.2290.019
call1600.001.152.202.2362.000.000.070-0.2320.019
call1650.004.901.802.33334.000.000.068-0.2360.018
call1700.004.900.002.3550.000.000.060-0.2180.017
put40.000.004.900.004.3150.000.00-0.065-0.4200.018
put45.000.004.901.803.7821.000.00-0.074-0.4110.020
put50.000.004.902.653.3061.000.00-0.086-0.3990.022
put55.000.004.900.002.8820.000.00-0.098-0.3850.024
put60.000.004.900.002.4780.000.00-0.114-0.3670.027
put65.000.004.902.202.1071.000.00-0.132-0.3470.030
put70.000.004.902.441.75510.000.00-0.156-0.3230.034
put75.000.004.900.501.42313.000.00-0.188-0.2950.038
put80.000.004.901.501.0911120.00-0.235-0.2570.043
put85.000.202.602.500.79630.000.00-0.342-0.2490.052
put90.001.505.5011.000.88831.000.00-0.501-0.2800.056
put95.005.008.709.000.8611.000.00-0.597-0.3670.054
put1009.0013.2018.251.0206.000.00-0.682-0.3520.050
put10514.0018.1015.001.2123.000.00-0.861-0.1460.031
put11019.0022.900.001.4000.000.00-0.878-0.1570.028
put11524.0028.000.001.5520.000.00-0.890-0.1680.026
put12029.0033.000.001.7120.000.00-0.899-0.1760.025
put12534.0037.700.001.7680.000.00-0.906-0.1830.024
put13039.0042.700.001.9040.000.00-0.911-0.1890.022
put13544.0048.000.002.1330.000.00-0.916-0.1950.022
put14049.0052.7032.802.1540.000.00-0.920-0.2000.021
put14554.0057.700.002.2690.000.00-0.923-0.2040.020
put15059.0062.700.002.3790.000.00-0.926-0.2080.020
put15564.0067.700.002.4830.000.00-0.928-0.2120.019
put16069.0072.700.002.5830.000.00-0.930-0.2150.019
put16574.0077.700.002.6790.000.00-0.932-0.2190.018
put17079.0082.700.002.7710.000.00-0.934-0.2210.018

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-30SCHEDULE 13GSEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-18S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13GSEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09004.49M2
2026-080021.63M6
2026-07003.16M1
2026-06004.83M2
2026-050051.20K1
2026-0400738.84K1
2026-030028.03M6
2026-020000
2026-010000
2025-1200903.60K1
2025-11007.38M2

Institutional holders

Manager% owned
FMR LLC15.29%
BlackRock, Inc.7.54%
T. Rowe Price Investment Management, Inc.7.11%
WELLINGTON MANAGEMENT GROUP LLP5.91%
Fairmount Funds Management LLC4.64%
PRICE T ROWE ASSOCIATES INC /MD/4.60%
STATE STREET CORP4.31%
VANGUARD CAPITAL MANAGEMENT LLC3.95%
Avidity Partners Management LP3.85%
Octagon Capital Advisors LP3.37%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
Fidelity Growth Company Fund2.85%
VANGUARD HEALTH CARE FUND2.75%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.38%
iShares Russell 2000 ETF2.22%
T. Rowe Price Small-Cap Stock Fund, Inc.2.11%
Fidelity Advisor Biotechnology Fund1.34%
T. Rowe Price New Horizons Fund, Inc.1.23%
T. Rowe Price Institutional Small-Cap Stock Fund1.14%
Fidelity Small Cap Index Fund0.95%

OakChart. DNTH. Cached 15 minutes.